{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:12Z","timestamp":1792787232913,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Health and Labour Sciences Research"},{"name":"Promotion of Drug Development from the Ministry of Health"},{"name":"Labour and Welfare of Japan"},{"name":"Chugai Pharmaceutical Co. Ltd","id":[{"id":"https:\/\/ror.org\/01v743b94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Chugai Pharmaceutical Co. Ltd","id":[{"id":"https:\/\/ror.org\/01v743b94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.neuint.2018.10.012","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T15:52:30Z","timestamp":1539791550000},"page":"104315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Blockade of IL-6 signaling in neuromyelitis optica"],"prefix":"10.1016","volume":"130","author":[{"given":"Manabu","family":"Araki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2018.10.012_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cen3.12394","article-title":"Neuromyelitis optica spectrum disorders: emerging therapies","volume":"8","author":"Araki","year":"2017","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.neuint.2018.10.012_bib2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","volume":"23","author":"Araki","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.neuint.2018.10.012_bib3","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.10.012_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0006-8993(00)02807-9","article-title":"Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain","volume":"879","author":"Arruda","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2018.10.012_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuint.2018.10.012_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrneurol.2014.129","article-title":"Pain in neuromyelitis optica\u2013prevalence, pathogenesis and therapy","volume":"10","author":"Bradl","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuint.2018.10.012_bib7","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuint.2018.10.012_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083036","article-title":"Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica","volume":"8","author":"Chihara","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.neuint.2018.10.012_bib9","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.10.012_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1759-1961.2012.00030.x","article-title":"Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease","volume":"3","author":"Fujihara","year":"2012","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.neuint.2018.10.012_bib11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","article-title":"Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation","volume":"102","author":"Ganz","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.neuint.2018.10.012_bib12","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.10.012_bib13","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","article-title":"Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2","volume":"205","author":"Hinson","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuint.2018.10.012_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.neuint.2018.10.012_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.neuint.2018.10.012_bib16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neuint.2018.10.012_bib17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"International Multiple Sclerosis Genetics Consortium","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuint.2018.10.012_bib18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/jnnp-2012-302310","article-title":"Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders","volume":"84","author":"Jacob","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuint.2018.10.012_bib19","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.neuint.2018.10.012_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5414\/NP300697","article-title":"Evidence for classic complement activity in neuromyelitis optica","volume":"33","author":"Jones","year":"2014","journal-title":"Clin. Neuropathol."},{"key":"10.1016\/j.neuint.2018.10.012_bib21","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.neuint.2018.10.012_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuint.2018.10.012_bib23","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.neuint.2018.10.012_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuint.2018.10.012_bib25","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.neuint.2018.10.012_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuint.2018.10.012_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2018.10.012_bib28","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.neuint.2018.10.012_bib29","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/0961203312441046","article-title":"Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus","volume":"21","author":"Maeshima","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.neuint.2018.10.012_bib30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0166-2236(00)01746-X","article-title":"The link between excitotoxic oligodendroglial death and demyelinating diseases","volume":"24","author":"Matute","year":"2001","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuint.2018.10.012_bib31","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuint.2018.10.012_bib32","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","article-title":"Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels","volume":"18","author":"Nakashima","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.neuint.2018.10.012_bib33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuint.2018.10.012_bib34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.neuroscience.2004.06.076","article-title":"Freeze-fracture and immunogold analysis of aquaporin-4 (AQP4) square arrays, with models of AQP4 lattice assembly","volume":"129","author":"Rash","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuint.2018.10.012_bib35","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuint.2018.10.012_bib36","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuint.2018.10.012_bib37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ana.24208","article-title":"Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks","volume":"76","author":"Sato","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuint.2018.10.012_bib38","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.10.012_bib39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X10378372","article-title":"The role of interleukin 6 in the pathophysiology of rheumatoid arthritis","volume":"2","author":"Srirangan","year":"2010","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.neuint.2018.10.012_bib40","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/rheumatology\/kes131","article-title":"Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study","volume":"51","author":"Strand","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.neuint.2018.10.012_bib41","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.neuint.2018.10.012_bib42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.smim.2014.01.009","article-title":"A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy","volume":"26","author":"Tanaka","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.neuint.2018.10.012_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuint.2018.10.012_bib44","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.neuint.2018.10.012_bib45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bpa.12097","article-title":"Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications","volume":"24","author":"Uzawa","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuint.2018.10.012_bib46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1533-2500.2010.00367.x","article-title":"The role of glia and the immune system in the development and maintenance of neuropathic pain","volume":"10","author":"Vallejo","year":"2010","journal-title":"Pain Pract."},{"key":"10.1016\/j.neuint.2018.10.012_bib47","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","article-title":"Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment","volume":"181","author":"Vincent","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuint.2018.10.012_bib48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0929-6646(11)60074-0","article-title":"Microglia: a promising target for treating neuropathic and postoperative pain, and morphine tolerance","volume":"110","author":"Wen","year":"2011","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.neuint.2018.10.012_bib49","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.10.012_bib50","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.10.012_bib51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.10.012_bib52","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1177\/1352458514522103","article-title":"Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life","volume":"20","author":"Zhao","year":"2014","journal-title":"Mult. Scler."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018618303589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018618303589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:46:20Z","timestamp":1759311980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018618303589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":52,"alternative-id":["S0197018618303589"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2018.10.012","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blockade of IL-6 signaling in neuromyelitis optica","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2018.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104315"}}